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Abstract The objective of the study was the assessment of
serum levels and tissue expression ofmatrixmetalloproteinase
2 (MMP-2) and tissue inhibitor of matrix metalloproteinases 2
(TIMP-2) in patients with colorectal cancer (CRC). The study
included 72 CRC patients and 68 healthy subjects. The serum
levels of MMP-2 and TIMP-2 were measured using enzyme-
linked immunosorbent assay (ELISA) method, whereas tissue
expression of MMP-2 and TIMP-2 in cancer cells, interstitial
inflammatory cells, and adjacent normal colorectal mucosa
were examined by immunohistochemical staining of tumor
samples. The serum levels of MMP-2 and TIMP-2 in cancer
patients were significantly lower than those in control group,
but the percentage of positive immunoreactivity of these pro-
teins were higher in malignant and inflammatory cells as
compared to normal tissue. There was a significant correlation
between MMP-2 immunoreactivity in inflammatory cells and
the presence of distant metastases and between TIMP-2 ex-
pression in inflammatory cells and tumor size, nodal
involvement, and distant metastases. Area under receiver op-
erating characteristic (ROC) curve (AUC) for serum MMP-2
was higher than for serum TIMP-2. Moreover, positive tissue
expression of MMP-2 was a significant prognostic factor for
CRC patients’ survival. Our findings suggest that MMP-2 and
TIMP-2 might play a role in the process of colorectal cancer
invasion and metastasis, but the significance of their interac-
tions with tumor stroma and interstitial inflammatory infiltra-
tion in colorectal neoplasia require further elucidation.
Keywords Colorectal cancer . Matrixmetalloproteinase 2 .
Tissue inhibitor ofmatrix metalloproteinases 2 .
Immunohistochemical staining
Introduction
Colorectal cancer (CRC) is one of the most frequent malignant
tumors in the industrialized world [1]. Colorectal carcinogen-
esis is a complex, long-term process and includes several steps
of malignant transformation from normal epithelium to cancer
cells, which involves numerous genetic changes and results in
various phenotypic alterations [2]. The next step of tumor
development is the degradation of basement membrane and
invasion of epithelium that leads to metastasis of cancer cells
into distant organs [3]. Various proteases are involved in
cancer progression and metastasis. Matrix metalloproteinases
are synthesized by neoplastic and stromal cells [3]. In partic-
ular, matrix metalloproteinase 2 (MMP-2) and MMP-9,
known as gelatinases, have been implicated to play a signifi-
cant role in colon cancer progression and metastasis. Levels of
the MMP-2 gene expression in colorectal tumors were lower
than in adjacent normal mucosa and significantly correlated
with the depth of invasion, venous invasion, and presence of
liver metastasis [4]. Moreover, plasma MMP-2 levels were
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lower in CRC metastatic liver disease than in healthy controls
[5]. However, Wu et al. revealed that the expression of MMP-
2 protein was significantly increased in CRC tissues, whereas
in normal colorectal cells, it was not detected [6].
Neoplastic tumors consist of cancer and nonmalignant
cells, the latter also contribute in MMPs expression in tumors.
These enzymes are expressed by fibroblasts, macrophages,
monocytes, dendritic cells, natural killer cells, lymphocytes,
and neutrophils [7]. MMP-2 mRNA in colon cancer tumors is
mainly localized in fibroblasts, and it seems that the main
source of MMP-2 in colorectal tumors is fibroblasts.
However, a number of other cells involved in tumor biology
have been found to express this proteinase. Thus, the expres-
sion of gelatinases in tumors is not only a consequence of their
expression in cancer cells. Various immune cells express
either MMP-2 or MMP-9 or both. The primary function of
gelatinases is probably related with migration of immune
cells. Cancer cells may use host cell gelatinases for their
own purpose by modulation of MMP expression in host cells.
Moreover, in combination with suppression of the immune
response, they use host-derived gelatinases for their own
advantage [8].
Remodeling of normal and tumor tissue may be a result of
imbalance between MMPs, and their natural inhibitors—tis-
sue inhibitors of matrix metalloproteinases (TIMPs) [9–12].
Li and coworkers [13] have shown that the imbalance between
MMP-2 activity and its specific inhibitor TIMP-2 in colorectal
tumor tissue might be a significant factor in the process of
cancer invasion and metastasis. It was shown that the expres-
sion of MMP-2 in CRC tissues was significantly higher, but
TIMP-2 was significantly lower than that in normal tissues
[13]. Additionally, the MMP-2/TIMP-2 ratio was higher in
CRC than in normal tissues and gradually decreased with
tumor stage, depth of invasion, and lymph node metastasis
[13]. In our previous study, the serum levels of MMP-2 and
TIMP-2 were significantly lower in CRC patients than in
healthy subjects and decreased with tumor stage [14].
However, according to the best of our knowledge, there is
no study comparing serum levels of MMP-2 and TIMP-2 in
colorectal cancer patients with their expression in colorectal
tumor tissue: cancer cells, inflammatory infiltrate cells, and
colorectal cells from adjacent normal tissue.
Therefore, the aim of the present study was to assess the
concentrations of MMP-2 and TIMP-2 in the sera of CRC
patients as well as immunohistochemical expression of these
proteins in various types of cells in the tumors. We determined
the serum levels and tumor tissue expression of MMP-2 and
TIMP-2 in 72 CRC patients in relation to clinicopathological
features of cancer as well as the prognostic significance of all
variables tested for CRC patients’ survival. Moreover, we
examined serum levels of MMP-2 and TIMP-2 in 68 healthy
controls and assessed the areas under receiver operating char-
acteristic (ROC) curves (AUCs) for both serum proteins.
Material and methods
Patients
The study included 72 previously untreated CRC patients
which were diagnosed and operated on in the Second
General and Gastroenterological Surgery Department of
Białystok Medical University Hospital as well as a control
group of 68 healthy volunteers. The study was approved by
the local ethics committee, and the study number is R-I-002/
443/2010. All the patients gave their informed consent to
participate in the study.
In the clinical diagnosis of CRC patients, the physical
examination, blood tests, chest X-rays, abdominal ultrasound,
and computed tomography were used. A heart attack, heart
failure, presence of extraintestinal tumors, and preoperative
radio-chemotherapy were the factors which exclude patients
from the study. The material obtained during colonoscopy
and/or surgery from all cancer patients was subjected to mi-
croscopic evaluation.
Sixty-eight cancer patients underwent surgical tumor re-
section, whereas nonresectable tumors were diagnosed in four
subjects. After routine histopathological analysis of tumor
tissue, the cancer patients were assessed in accordance to
Duke’s classification [15]: 1 patient in stage A, 4 patients in
stage B1, 23 patients in stage B2, 19 patients in stage C1, 4
patients in stage C2, and 21 patients in stage D, and they were
then subdivided into four groups depending on the infiltration
of the bowel wall (T1, T2, T3, and T4), four groups in relation
to nodal involvement (N0, N1, N2 and N3), and two groups
regarding the absence or presence of distant metastases (M0
and M1). Eight colorectal cancer patients died of cancer
during the 2-year observation period, whereas 42 patients
survived. The number of patients in the analyzed subgroups
is presented in Table 1.
Protein analyses
Venous blood samples from all the patients were drawn before
any surgical treatment, chemo- or radiotherapy. All blood
samples were allowed to clot before centrifugation. Sera were
removed, aliquoted, and stored at −80 °C until assayed. Serum
concentrations of MMP-2 and TIMP-2 were measured using
enzyme-linked immunosorbent assay (ELISA) kits (R&D
Systems, Abingdon, England) according to the manufac-
turer’s instructions. The serum samples were diluted 10-fold
for the determination of MMP-2 and 50-fold for the measure-
ment of TIMP-2. The intra-assay coefficient of variation
(CV%) of MMP-2 is reported by the manufacturer to be
5.8 % at a mean concentration of 18.9 ng/mL, SD=1.1, and
that of TIMP-2 is reported to be 4.4 % at a mean concentration
of 1.23 ng/mL, SD=0.054. The reference cutoff values for
serum levels of proteins tested were established previously
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[14]. The cutoff points were 160 ng/mL for MMP-2 and
85 ng/mL for TIMP-2. The positive results of MMP-2 and
TIMP-2 are below cutoff values.
Immunohistochemical staining
The tissue specimens were fixed in 10 % solution of buffered
formalin and then dehydrated and embedded in paraffin.
Obtained paraffin blocks were cut on microtome into
5-μm-thick sections, which were heated in a microwave to
visualize antigen. For the detection of MMP-2 and TIMP-2
in the tissue samples, the mouse monoclonal antibodies
(NCL-MMP2-507 and NCL-TIMP2-487, respectively) were
used (Novocastra). The antigen–antibody complex was visu-
alized by means of DAB chromogen (Novocastra). The im-
munoreactivity of MMP-2 and TIMP-2 in cancer cells was
evaluated with light microscopy. Additionally, the intensity of
the metalloproteinase and its inhibitor in inflammatory infil-
trate cells (macrophages, polynuclears, and lymphocytes) in
the neoplastic interstitium as well as in normal colorectal
tissue from adjacent tumor mucosa was evaluated in the same
tumor samples.
Statistical analysis
The tumor stages A, B1, and B2 were analyzed as one group
(stage A + B1 + B2) whereas stages C1 and C2 as stage C1 +
C2 because of small numbers of patients in the particular
subgroups. Similarly, the T1, T2, and T3 patients were ana-
lyzed as T1 + T2 + T3 subgroup whereas N1, N2, and N3
patients as N1 + N2 + N3 tumors.
The serum levels of MMP-2 and TIMP-2 did not follow a
normal distribution based on Kolmogorov–Smirnov and
Shapiro–Wilk tests. Therefore, nonparametric statistical anal-
yses were used in the next step. The Mann–Whitney U test
was used to compare the two groups in each category (CRC
versus healthy controls; colon cancer versus rectal cancer;
T1 + T2 + T3 versus T4 or N0 versus N1 + N2 + N3; M0
versus M1 group; resectable tumors versus nonresectable; the
group of patients who survived versus patients who died of
CRC). Differences betweenmore than two groups (e.g., stages
A + B1 + B2, C1 + C2, D) were compared using ANOVA on
ranks (Kruskal–Wallis tests). If significant differences were
found in Kruskal–Wallis test, we conducted the post hoc
Dwass–Steele–Critchlow–Fligner test to determine which
pairs of subgroups were different. Data are presented as me-
dian and range. Differences were considered statically signif-
icant with p values below 0.05.
Moreover, we calculated diagnostic criteria, such as ROC
AUC for the MMP-2 and TIMP-2. The AUC for proteins
tested was compared with AUC=0.5 using the method de-
scribed by Hanley and Hajian-Tilaki [16].
The tumor samples were indicated as positive and negative
due to the presence or absence of MMP-2 or TIMP-2 immu-
noreactivity in three types of cells: cancer cells, interstitial
inflammatory infiltrate, and normal colorectal tissue within
tumor samples. The intensity of immune reaction of MMP-2
and TIMP-2 was evaluated in semiquantitative scale: 0 pt, no
reaction; 1 pt, weak reaction; 2 pts, moderate reaction; and 3
pts, intense reaction. The immunoreactivity of each subgroup
was analyzed as negative (0 pt) or positive (1 or 2 or 3 pts)
expression. The presence of tissue expression of proteins
tested is shown as a number of cases and percentages in each
subgroup analyzed.
Table 1 Characteristics
of patients Characteristics No.



























Distant metastases (M factor)
M0 51
M1 21
Survival of patients (n =50)
Alive 42
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The correlations between tissue expression of MMP-2
and TIMP-2 and clinicopathological parameters of tumor
were assessed using Fisher exact probability test and
Fisher–Freeman–Halton test [17]. The Spearman rank cor-
relation test was employed for the analyses of correlations
between serum levels and tissue expression of MMP-2 and
TIMP-2 in colorectal cancer patients. The patients’ univariate
analyses were estimated using the log-rank test, and multivar-
iate analyses employed Cox proportional hazards model. For
all multivariate analyses, forward stepwise procedures
were used. Statistical analyses were carried out using the
STATISTICA 9.0 PL program (StatSoft, Inc., Tulsa, OK).
Diagnostic criteria and the ROC curves were calculated using
MedCalc statistical software (MedCalc Software, Mariakerke,
Belgium) and Microsoft Office Excel program (Microsoft
Corporation, Redmond, WA).
Results
Serum levels of MMP-2 and TIMP-2 in colorectal cancer
patients in relation to clinicopathological features of tumor
Concentrations (median and range) of MMP-2 and TIMP-2 in
the sera of colorectal cancer patients and healthy subjects are
presented in Table 2. Serum levels of MMP-2 and TIMP-2
were significantly lower in CRC patients than in healthy
controls. Serum levels of MMP-2 and TIMP-2 correlated with
tumor stage and were the lowest in CRC patients with stage D.
Concentrations of proteins tested were also lower in the sera of
patients with T4 tumors than in T1 + T2 + T3 group and in
CRC subjects with lymphatic nodes involved (N1 + N2 + N3
subgroup) than in patients without nodal metastases (N0).
Moreover, in patients with distant metastases, the serum
levels of MMP-2 and TIMP-2 were lower than those in
M0 subgroup. All the differences did not reach a statistical
significance.
The associations between the expression of proteins tested
and clinicopathological features of tumor
Table 3 presents the associations between the expression of
MMP-2 and TIMP-2 in various types of cells and clinicopath-
ological features of tumor. In colorectal cancer, the positive
reaction was observed in 23.6 % of cases in cancer cells
(Fig. 1) and 50 % of inflammatory infiltrate cells, whereas in
normal colorectal tissue surrounding tumor nests, the presence
of MMP-2 was observed only in one case.
The percentage of MMP-2-positive cases decreased with
tumor stage; it was the lowest in stage D as well in cancer cells
as in interstitial inflammatory infiltrate cells. Similar observa-
tions were made in inflammatory cells in relation to tumor size
(T factor) and nodal involvement (N factor); the highest
number of positive cases was seen in T1 + T2 subgroup and
in N0 patients. Moreover, in patients without distant metasta-
ses (M0 subgroup), the percentages of positive MMP-2 stain-
ing were higher than those in M1 subgroup, although the
differences between M0 and M1 tumors were significant only
for inflammatory cells (p =0.037).
The correlations between the expression of TIMP-2 and
clinicopathological features of tumor are also presented in
Table 3. The positive reaction was observed in 87.5 % of
Table 2 Serum levels of bio-
markers tested in colorectal can-
cer patients in relation to clinico-
pathological features of tumor
*p <0.05, statistically significant
Variable analyzed No. MMP-2 (ng/mL) TIMP-2 (ng/mL)
Median (range) p Median (range) p
Tested group
CRC 72 180 (87–476) <0.001* 81 (35–132) 0.003*
Control group 68 235 (108–384) 90 (54–141)
Tumor stage (Duke’s classification)
A + B1 + B2 28 180 (87–308) 0.548 82 (35–109) 0.804
C1 + C2 23 193 (110–361) 81 (68–109)
D 21 170 (121–476) 79 (59–132)
Tumor size (T factor)
T1 + T2 + T3 59 182 (87–479) 0.067 82 (35–132) 0.707
T4 13 136 (110–361) 79 (59–110)
Nodal involvement (N factor)
N0 30 182 (87–308) 0.851 82 (35–109) 0.621
N1 + N2 + N3 42 175 (110–476) 80 (59–132)
Distant metastases (M factor)
M0 51 182 (87–361) 0.372 82 (35–109) 0.733
M1 21 170 (121–476) 79 (59–132)
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cancer cells (Fig. 2), 75 % of inflammatory infiltrate cells, and
15.3% of normal cells. The percentages of positive cases were
the highest in stage C1 + C2 in all types of cells, although the
differences between tumor stages did not reach a statistical
significance. The ratio of TIMP-2-positive cases varied in
relation to T factor; the lowest number of positive cases was
observed in T4 tumors, whereas the highest percentage of
TIMP-2-positive cases among cancer cells was observed in
T3 subgroup, but in T1 + T2 tumors—in 100 % of inflamma-
tory cells (statistically significant difference with p =0.003).
Similarly, the number of TIMP-2-positive cases varied with
the number of lymphatic nodes involved. It was both in cancer
and inflammatory cells that the highest number of positive
cases was observed in N1 tumors, although the differences
within N subgroup were significant only for the expression of
TIMP-2 in inflammatory cells (p =0.007). The presence of
TIMP-2 in inflammatory cells was also significantly higher
(p =0.036) in M0 patients than in M1 subgroup.
Correlations between serum levels and tissue expression
of MMP-2 and TIMP-2 in colorectal cancer patients
Table 4 presents the associations between serum levels of
MMP-2 and TIMP-2 in CRC patients and the presence of
the expression of these proteins in three types of cells: colo-
rectal cancer cells, interstitial inflammatory infiltrate cells, and
normal colorectal cells. Serum levels of MMP-2 were signif-
icantly higher in patients with positive expression of this
protein in cancer cells (p =0.047) as well as in patients with
positive expression of TIMP-2 in inflammatory (p <0.001)
and normal colorectal cells (p =0.04).
These observations were confirmed in Spearman correla-
tion analysis (Table 5). The serum levels of MMP-2 correlated
significantly with serum levels of TIMP-2 in colorectal cancer
patients (p <0.001) and intensity of this protein expression
in inflammatory (p =0.012) and normal colorectal cells
(p =0.039). Moreover, the intensity of MMP-2 expression in
inflammatory cells correlated significantly with the expression
of this protein in cancer cells (p =0.006) and with the expres-
sion of TIMP-2 in all types of cells analyzed (p =0.040,
p =0.003, and p =0.0495, respectively). The expression of
TIMP-2 in inflammatory cells correlated significantly with the
expression of this protein in cancer and normal cells (p <0.001
and p =0.004, respectively).
Serum and tissue expression of MMP-2 and TIMP-2
as prognostic factors of patients’ survival
Univariate regression analysis showed that tumor stage
(p =0.027), presence of nodal (p =0.018) and distant metasta-
ses (p =0.006), tumor resectability (p =0.002), and presence
of MMP-2 expression in normal colorectal cells (p =0.030)
were significant factors for patients’ 2-year survival (Table 6).
Neither age, gender of CRC patients, and T factor nor serum
levels and expression of both proteins tested in other types of
cells were significant prognostic factors. Multivariate regres-
sion analysis with Cox proportional hazard model revealed
that none of factors analyzed were an independent prognostic
factor for the survival of CRC patients.
Diagnostic criteria for MMP-2 and TIMP-2 in CRC patients
The ROC AUC for MMP-2 (0.7402) was higher than the
AUC for TIMP-2 (0.6432) (Fig. 3). Additionally, AUC for
both proteins was significantly higher than value AUC=0.5
(p <0.001 for MMP-2 and p =0.002 for TIMP-2).
Discussion
Expression of genes encoding type IV collagen-degrading
metalloproteinases and tissue inhibitors of metalloproteinases
Fig. 1 Immunohistochemical staining. MMP-2 expression in cancer
cells (+2); original magnification, ×400
Fig. 2 Immunohistochemical staining. TIMP-2 expression in cancer
cells (+3); original magnification, ×400
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was detected in various human tumor cells, including colo-
rectal cancer [18]. Transcripts for MMP-2 were more fre-
quently expressed in mesenchymal tumor cells than in epithe-
lial tumor cells. Their activity was regulated by TIMPs, which
are induced mainly in stromal cells [18]. The immunohisto-
chemical expression of MMP-2 in CRC tumors is significant-
ly higher than that in adjacent normal tissues [13, 19].
However, little is known about the comparison of the levels
of MMP-2 and TIMP-2 in the sera of CRC patients with an
expression of MMP-2 and its inhibitor in colorectal cancer
tissue. Therefore, the aim of the study was to examine the
serum levels of MMP-2 and TIMP-2 in CRC patients and to
compare the serum concentrations of those proteins with their
presence and intensity expression in colorectal cancer cells,
interstitial infiltrate inflammatory cell, and normal colorectal
cells. We have also assessed the significance of MMP-2 and
TIMP-2 as prognostic factors of CRC patients’ survival.
In our study, the serum levels of MMP-2 and TIMP-2 in
CRC patients and healthy controls were assessed using an
ELISA method. We revealed that the concentrations of both
Table 4 Serum levels of bio-
markers tested in colorectal can-
cer patients in relation to presence
of MMP-2 and TIMP-2 expres-
sion in colorectal cancer cells, in-
terstitial inflammatory infiltrate
cells and in normal colorectal
tissue
*p <0.05, statistically significant
Variable analyzed No. Serum MMP-2 (ng/mL) Serum TIMP-2 (ng/mL)
Median (range) p Median (range) p
Expression of MMP-2 in colorectal cancer cells
Negative 55 176 (87–476) 0.047* 81 (35–132) 0.162
Positive 17 202 (145–361) 90 (64–110)
Expression of MMP-2 in inflammatory cells
Negative 36 172 (87–296) 0.128 83 (35–110) 0.761
Positive 36 185 (115–476) 81 (36–132)
Expression of MMP-2 in normal colorectal tissue
Negative 71 179 (87–476) 0.548 82 (35–132) 0.194
Positive 1 204 69
Expression of TIMP-2 in colorectal cancer cells
Negative 9 175 (114–230) 0.319 85 (73–92) 0.615
Positive 63 182 (87–476) 81 (35–132)
Expression of TIMP-2 in inflammatory cells
Negative 18 150 (87–230) <0.001* 78 (35–106) 0.080
Positive 54 199 (115–476) 83 (61–132)
Expression of TIMP-2 in normal colorectal tissue
Negative 61 175 (87–476) 0.040* 80 (35–132) 0.161
Positive 11 207 (159–3,170) 90 (68–110)















r (p) r (p) r (p) r (p) r (p) r (p) r (p)
Serum MMP-2 0.51 (<0.001*) 0.22 (0.064) 0.14 (0.239) 0.07 (0.551) 0.09 (0.458) 0.29 (0.012*) 0.24 (0.039*)
Serum TIMP-2 0.16 (0.187) 0.02 (0.844) −0.15 (0.196) −0.03 (0.802) 0.17 (0.153) 0.17 (0.163)
Tissue MMP-2 in
cancer cells
0.32 (0.006*) −0.07 (0.585) 0.06 (0.625) 0.11 (0.347) 0.12 (0.304)
Tissue MMP-2 in
inflammatory cells
0.09 (0.442) 0.24 (0.040*) 0.35 (0.003*) 0.23 (0.050*)
Tissue MMP-2 in
normal cells
−0.11 (0.365) −0.02 (0.899) −0.05 (0.674)
Tissue TIMP-2 in
cancer cells




r indicates correlation coefficient
*p <0.005, statistically significant
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proteins tested were significantly lower in cancer patients than
in healthy subjects, which is in agreement with our previous
results [14] as well as with the investigation of Waas et al.,
who have shown that plasma pro-MMP-2 levels were lower in
colorectal cancer patients than in healthy controls [20].
Moreover, in the study of Oberg et al., the serum levels of
the MMP-2/TIMP-2 complexes were significantly lower in
CRC patients as compared to healthy blood donors; however,
the serum levels of free MMP-2 and total TIMP-2 were
significantly higher in comparison with control group [21].
In the present paper, the concentrations of MMP-2 and
TIMP-2 in the sera of CRC patients revealed neither any
significant correlation with tumor stage, tumor size, and nodal
involvement nor with the presence of distant metastases,
although there was a tendency to decrease the levels of pro-
teins tested in more advanced tumors. This tendency is oppo-
site to the results obtained by of Angenete et al. who revealed
that plasma levels of MMP-2 were higher in CRC patients
with distant metastases [22]. However, our findings are in
accordance with the study of Langenskiöld et al. who had
found that plasma MMP-2 in CRC patients with T4 tumors
was lower than that in T3 and T1 + T2 subgroups [23]. The
decrease of serum MMP-2 and TIMP-2 in more advanced
tumor stages might be caused by the formation of MMP–
TIMP complexes in colorectal tumor progression. The differ-
ences between the results observed by cited authors and those
obtained in our present study might be the effects of the
complex function of MMP-2 and TIMP-2. It was suggested
that MMP-2 inhibition occurs at high levels of TIMP-2,
whereas low concentrations of the inhibitor are associated
with the activation of MMP-2 [24, 25].
It was suggested that in cancer tissue, the enhanced expres-
sion ofMMPs and TIMPs on the surface of inflammatory cells
might be a result of a host response induced by tumors [26]. In
the present paper, the tissue expression of MMP-2 and TIMP-
2 was observed in cancer and interstitial inflammatory infil-
trate cells as well as in normal colorectal epithelium. The
expression of both proteins was higher in cancer cell than in
normal tissue, where 15 % of normal colorectal cells
expressed the presence of TIMP-2 and only 1 % of normal
cells were MMP-2 positive, which is in line with the study of
Gershtein et al., who revealed that the content of MMP-2 in
tumors of patients with colorectal cancer was significantly
increased in comparison with the adjacent normal mucosa
[19]. Our results are also in accordance with the study of Wu
et al., who demonstrated an increased expression ofMMP-2 in
CRC tissues, but negative in normal colorectal tissues [6], and
with the paper of Kim et al. that also indicated higher levels of
MMP-2 protein in colon and rectal tumor tissues than in
corresponding paired normal mucosa, although, in their study,
TIMP-2 tissue levels were significantly lower in cancer than in
normal tissue [27]. Similarly, opposite results were obtained
by Li et al., who revealed that TIMP-2 expression in CRC
tissues was significantly lower than that in normal tissues [13].
Moreover, in our study, the highest percentage of positive
reactions of MMP-2 was observed in interstitial inflammatory
infiltrate cells. Obtained results may suggest that the main
source of MMP-2 in cancer tissue is rather interstitial inflam-
matory cells from tumor microenvironment than malignant
tumor cells. Our results may also confirm the role of
Table 6 Univariate Cox analysis of regression
Variable tested p HR
Age 0.997 1.000
Tumor stage (Duke’s classification) 0.086
C1 + C2 vs A + B1 + B2 0.970 0.000
D vs A + B1 + B2 0.027* 11.259
Tumor size (T factor) 0.230
T3 vs T2 0.962 9,271.216
T4 vs T2 0.956 34,627.135
Nodal involvement (N factor) 0.127
N1 vs N0 0.967 0.000
N2 vs N0 0.018* 14.347
N3 vs N0 0.054 11.127
Distant metastases (M factor) 0.006* 20.674
Resectability of tumor 0.002* 0.073
Serum MMP-2 0.968 1.000
Serum TIMP-2 0.662 1.009
Tissue MMP-2 in cancer cells 0.498 0.480
Tissue MMP-2 in inflammatory cells 0.331 2.281
Tissue MMP-2 in normal cells 0.030* 11.361
Tissue TIMP-2 in cancer cells 0.551 24.715
Tissue TIMP-2 in inflammatory cells 0.141 0.299
Tissue TIMP-2 in normal cells 0.445 0.035
*p <0.005, statistically significant
Fig. 3 ROC curves for serum levels of biomarkers analyzed: MMP-2
(AUC=0.7402) and TIMP-2 (AUC=0.6432)
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inflammation in carcinogenesis of colorectal cells, which was
suggested by other authors and in our previous study [28–30].
Interestingly, in both types of cells, the higher percentages
of positive immunoreactivity were shown for TIMP-2 than for
MMP-2; in cancer cells, we observed TIMP-2 immunostain-
ing in 87.5 % cases in comparison with 23.6 % of MMP-2
positivity, whereas 75 % of inflammatory cells were TIMP-2
positive in comparison with 50 % of inflammatory cells with
MMP-2 immunoreactivity. Our observations are in line with
the results of Schwandner et al., who demonstrated thatMMP-
2 tumor expression was positive in 35 % of epithelial malig-
nant cells, whereas there was an expression of TIMP-2 in
47 % of cases in rectal carcinoma [31].
In our current study, the correlations between expression of
both proteins tested and clinicopathological features of CRC
were evaluated.We did not confirm any significant correlation
between MMP-2 and TIMP-2 expression in colorectal cancer
cells or normal cells and tumor stage, tumor size (T), nodal
involvement (N), presence of distant metastases (M), or re-
sectability of tumor. In inflammatory cells, the expression of
MMP-2 revealed a significant correlation with M factor and
was higher in patients without distant metastases. The signif-
icant differences were also found for TIMP-2 expression in
inflammatory infiltrate cell; the percentage of positive reac-
tions decreased in patients with higher tumor size, number of
lymph node involved, and metastases to distant organs. The
opposite results were obtained by Jung et al., who demonstrat-
ed that the upregulation of TIMP-2 in submucosal colorectal
cancer tissue was positively correlated with adjacent lymphat-
ic vessel invasion and lymph node metastasis in submucosally
invasive colorectal carcinoma [32].
Additionally, we compared serum levels of proteins tested
with their tissue expression. We demonstrated that MMP-2
serum levels were significantly higher in patients with positive
expression of this enzyme in cancer cells and in CRC patients
with positive expression of TIMP-2 in inflammatory and
normal cells. The observations are in agreement with the
results of Spearman correlation test, which shows a significant
positive association between serumMMP-2 concentration and
expression of its inhibitor in the same types of cells as well as
between serum levels of both proteins. These findings suggest
a complex role of MMP-2/TIMP-2 network in colorectal
cancer development and metastasis.
Strong expression of many MMPs has been related to poor
survival of CRC patients. The expression of various TIMPs
has been associated with both a beneficial and a poor out-
come. Thus, there is a need to further clarify the significance
of MMPs and TIMPs in CRC. In the present study, we also
investigated whether the serum concentrations of MMP-2 and
TIMP-2 and intensity of their expression in various types of
cell might be useful prognostic factors for survival of CRC
patients. The univariate regression analysis indicated only the
presence of MMP-2 expression in normal colorectal cells as a
significant prognostic factor for patients’ survival, although
not independent on tumor stage. Our observations indicate
that the expression of MMP-2 in normal mucosa of CRC
patients could also be relevant as well to the outcome in cancer
cells. Our results are also in line with the study of Langers
et al. [33], who have shown that a high expression of MMP-2
in the normal colorectal mucosa was associated with reduced
survival of CRC patients.
Additionally, our results show the tumor stage, nodal in-
volvement, presence of distant metastases, and tumor resect-
ability, but not serum MMP-2 nor TIMP-2 as the significant
prognostic factors in CRC patients in univariate analysis.
Obtained results are in agreement with our previous
study [14], where preoperative serum MMP-2 and TIMP-2
levels were not prognostic markers for CRC patients. Similar
observations were also demonstrated by Waas et al. [5],
who showed that preoperative plasma pro-MMP-2 levels
had no potential value as prognostic markers in colorectal
cancer.
In the present paper, we defined the ROC AUC for the
proteins tested to assess a potential clinical significance of
MMP-2 and TIMP-2 in the diagnosis of CRC. We found that
AUC for serum MMP-2 (0.740) was higher than for TIMP-2
(0.643), and both were significantly higher than AUC=0.5.
These results suggest the potential clinical usefulness of
pretreatment serum MMP-2 and TIMP-2 as tumor markers in
CRC.
In conclusion, the aim of the present study was to assess the
serum levels of MMP-2 and TIMP-2 as well as tumor tissue
expression of these proteins in patients with colorectal cancer.
We have found the significant associations between decreased
MMP-2 expressions in inflammatory cells and distant metas-
tases as well as between tumor invasion and reduced expres-
sion of TIMP-2 in inflammatory interstitium. Moreover, the
immunoreactivity of MMP-2 and TIMP-2 in colorectal cancer
tissue correlated with the expression of these proteins in the
interstitial inflammatory infiltrate cells as well as with the
serum levels of TIMP-2 in CRC patients. The area under
ROC curve for serum levels of proteins tested was
higher for MMP-2 than for TIMP-2, what indicates a
possible clinical significance of serum MMP-2 in the
diagnosis of CRC, while the tissue expression of MMP-
2 as a prognostic factor of patients’ survival. Our results
suggest a complex network of interactions between tumor,
its microenvironment, and stromal cells, but this issue requires
further investigations.
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